(278) Melting the Iceberg – Nanomedicines-driven Matrix Remodeling and Immune Recruitment in PDAC
Introduction: While immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, pancreatic cancer (PDAC) remains one of the most ICI-resistant tumors [1]. Its unique dense stroma and immunosuppressive tumor microenvironment (TME) limit immune cell infiltration and therapeutic efficacy. Here, we demonstrate how nanomedicines overcome these barriers and drive an effective response against PDAC. We developed a crosslinked nanoconjugate carrying a FAK inhibitor (FAKi) to remodel PDAC stroma and dendritic cell (DC)-targeted polymeric nanoparticles to recruit effective immune cells into the TME.
Learning Objectives:
Nanomedicines unlock the dense and highly immunosuppressive tumor microenvironment.
Nanomedicines enhanced anti-tumor immune responses against pancreatic cancer.
St-PGA-FAKi and PLA/PLGA NPs improved survival rates in pancreatic cancer.
Inmaculada Conejos-Sanchez, n/a – Researcher, Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF); María Vives, n/a – PhD student, Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF); María Vicent, n/a – Principal Researcher, Polymer Therapeutics Laboratory, Prince Felipe Research Center (CIPF); Ronit Satchi-Fainaro, n/a – Full Professor, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University; Helena Florindo, n/a – Full Professor, iMed.ULisboa, Faculty of Pharmacy, University of Lisbon
